MarketWatch

Microbiotica reveals novel mechanisms showing how the microbiome can improve immunotherapy response based on MB097, a clinical-stage drug candidate being evaluated in ...

CAMBRIDGE, United Kingdom, April 29, 2025 (GLOBE NEWSWIRE) -- Microbiotica, a clinical-stage biopharma company developing a pipeline of oral precision microbiome medicines called live biotherapeutic ...
WGNO

Microbiotica presented new data on the mechanism of action of MB097, a clinical-stage drug candidate being developed as a co-therapy in combination with KEYTRUDA ...

CAMBRIDGE, United Kingdom, Feb. 26, 2025 (GLOBE NEWSWIRE) -- Microbiotica, a clinical-stage biopharma company developing a pipeline of oral precision microbiome medicines called live biotherapeutic ...
ascopubs.org

Phase 2 trial of TU2218, TGFβ-RI, and VEGF-R2 dual inhibitor in combination with pembrolizumab in patients with biliary tract cancer and head and neck cancer.

Phase II basket study to evaluate the tissue-agnostic efficacy of anti-PD1 in patients with advanced rare tumors: The ANTARES trial. This is an ASCO Meeting Abstract from the 2025 ASCO Annual Meeting ...
ascopubs.org

Immunotherapy vs. chemotherapy run-in followed by pembrolizumab plus nab-paclitaxel in metastatic triple negative breast cancer (mTNBC): Results from a phase II study.

Trop2-targeted PET/CT with 68Ga-MY6349 for the diagnosis of primary and metastatic breast cancer and evaluation towards patient stratification in Trop2-targeted ADCs.